Hormone replacement therapy in women with liver disease

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue 1, 1997, Pages 1-3

  O’Donohue, John ^a   Williams, Roger ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; ESTROGEN; ETHINYLESTRADIOL; PROGESTERONE;

CHOLESTASIS; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIVER DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY;

BONE DISEASES; CHOLESTASIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; PATIENT SELECTION; RISK FACTORS;

EID: 0031034374     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb10638.x     Document Type: Note

References (27)

1. Bonkovsky HL, Hawkins M, Steinberg K et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12: 273–280.
2. Lindor KD. Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis. Semin Liver Dis 1993; 13: 367–373.
3. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann lnt Med 1985; 103: 855–860.
4. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7: 137–142.
5. Tohme J, Cosmn F, Lindsay R. Osteoporosis. In: Becker KL, editor. Principles and Practices of Endocrinology and Metabolism. JB Lippincott, 1995: 567–585.
6. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341: 797–801.
7. Chow J, Tobias JH, Colston KW, Chamber TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of of bone formation. J Clin Invest 1992; 89: 74–78.
8. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; 2: 1151–1154.
9. Clements D, Compston JE, Evans WD, Smith PM. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543–1546.
10. Brink HR, Lems WF, Everdingen AA, Bijilsma JWJ. Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis. Ann Rheum Dis 1993; 52: 302–305.
11. Taurelle R. Substitutive hormone therapy in postmenopausal osteoporosis. Are there any contraindications Rev Fr Gynecol Obstet 1993; 88: 430–434.
12. Svanborg A. A study of recurrent jaundice in pregnancy. Acta Obstet Gynecol Scand 1954; 33: 434–444.
13. Eisalo A, Jarvinen PA, Luukkainen T. Hepatic impairment during the intake of contraceptive pills: clinical trials in postmenpausal women. BMJ 1964; 2:426–427.
14. Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinaemia (Dubin-Johnson syndrome). Gastroenterology 1972; 62: 1182–1190.
15. Schreiber AJ, Simon FR. Estrogen- induced cholestasis: clues to pathogenesis and treatment. Hepatology 1983; 3: 607–613.
16. Van-Erpecum KJ, Van-Berge-Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482–488.
17. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–197.
18. Moore B, Paterson M, Sturdee D. Effect of oral hormone replacement therapy on liver function tests. Maturitas 1987; 9: 7–15.
19. Darj E, Axelsson O, Carlstrom K, Nilsson S, von Schoultz B. Liver metabolism during treatment with estradiol and natural progesterone. GynecolEndocrinol 1993; 7: 111–114.
20. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am JGastroenterol 1994; 89: 47–50.
21. Guattery JM, Faloon WW. Effect of estradiol upon serum enzymes in primary biliary cirrhosis. Hepatology 1987; 7: 737–742.
22. Kable WT, Gallagher JC, Nachtigall L, Goldgar D. Lipid changes after hormone replacement therapy for menopause. J Reprod Med 1990; 35: 512–518.
23. Speroff L. Postmenopausal hormone replacement therapy and breast cancer. Obstet Gynaecol 1996; 87 Suppl 2: 44S–54S.
24. Theriault RL. Hormone replacement therapy and breast cancer: an overview. Br. J. Obstet. Gynaecol 1996; 103 Suppl 13: 87–91.
25. Kafonek SD. Postmenopausal hormone replacement therapy and cardiovascular risk reduction. Drugs 1994; 2: 16–24.
26. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI. Oral versus transdermal HRT. Int J Fertil Menopausal Stud 1993; 38 Suppl 1:30–35.
27. Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978; 1: 1325–1327.